{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:39Z","timestamp":1793766459807,"version":"4.6.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102649","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:35Z","timestamp":1787181935000},"page":"102649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Efficacy and Safety of Belzutifan in Sporadic Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Yu Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedyeh","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Zugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6194-6660","authenticated-orcid":false,"given":"Jadon","family":"Fann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Jaime-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarsan V.","family":"Kollimutthaumillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-4540","authenticated-orcid":false,"given":"Sandy T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-4527","authenticated-orcid":false,"given":"Alex","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele A.","family":"Adesunloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-5501","authenticated-orcid":false,"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clgc.2026.102649_bib0001","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"10397","key":"10.1016\/j.clgc.2026.102649_bib0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.clgc.2026.102649_bib0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clgc.2026.102649_bib0004","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2026.102649_bib0005","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","article-title":"FDA approval summary: belzutifan for patients with advanced renal cell carcinoma","volume":"30","author":"Fallah","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102649_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.18632\/oncotarget.27428","article-title":"Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes","volume":"11","author":"Buscheck","year":"2020","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.clgc.2026.102649_bib0007","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/3.12.2169","article-title":"Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma","volume":"3","author":"Foster","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.clgc.2026.102649_bib0008","first-page":"1942","article-title":"VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation","volume":"60","author":"Brauch","year":"2000","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102649_bib0009","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/gim.2017.261","article-title":"Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-alpha binding site in VHL protein","volume":"20","author":"Liu","year":"2018","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102649_bib0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/iju.13424","article-title":"Ethnic disparities in renal cell carcinoma: an analysis of Hispanic patients in a single-payer healthcare system","volume":"24","author":"Suarez-Sarmiento","year":"2017","journal-title":"Int J Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102649_bib0011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oncolo\/oyad190","article-title":"Real-world outcomes of Latinx versus Non-Latinx patients treated with first-line immunotherapy for metastatic renal-cell carcinoma","volume":"28","author":"Chehrazi-Raffle","year":"2023","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.clgc.2026.102649_bib0012","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.urolonc.2018.05.006","article-title":"An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States","volume":"36","author":"Kaldany","year":"2018","journal-title":"Urol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102649_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e18672","article-title":"Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End results (SEER) cancer patient registry data in advanced renal cell carcinoma (aRCC)","volume":"41","author":"Garretson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102649_bib0014","doi-asserted-by":"crossref","first-page":"12792","DOI":"10.1002\/cam4.5929","article-title":"Clear cell renal cell carcinoma molecular variations in non-Hispanic white and Hispanic patients","volume":"12","author":"Batai","year":"2023","journal-title":"Cancer Med"},{"issue":"4_Suppl","key":"10.1016\/j.clgc.2026.102649_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2024.42.4_suppl.372","article-title":"Comparing molecular variations and outcomes in Hispanic and non-Hispanic patients with metastatic clear cell renal cell carcinoma (ccRCC)","volume":"42","author":"Choi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102649_bib0016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102649_bib0017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.euf.2025.04.019","article-title":"A practical guide for the management of toxicities associated with Belzutifan","volume":"11","author":"Li","year":"2025","journal-title":"Eur Urol Focus"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:50Z","timestamp":1793765810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001497"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102649","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Efficacy and Safety of Belzutifan in Sporadic Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102649"}}